Taro Pharmaceutical Industries Ltd (NYSE:TARO)
| 40.95 Delayed Data As of Jun 09 |  +1.76 / +4.49%Today’s Change | 22.89 Today|||52-Week Range 41.87 | +41.01% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $1.4B |
Company Description
Taro Pharmaceutical Industries Ltd. engages in the development, manufacturing and marketing of prescribed and over-the-counter pharmaceutical products in the U.S., Canada and Israel. Its products include semi-solids formulations, such as creams and ointments and other dosage forms such as liquids, capsules and tablets, in the dermatological and topical, cardiovascular, neuropsychiatric and anti-inflammatory therapeutic categories. The company was founded in 1950 and is headquartered in Haifa Bay, Israel.
Contact Information
Taro Pharmaceutical Industries Ltd. 14 Hakitor Street Haifa Bay Haifa 2624761 |
Employees
Shareholders
| Other institutional | 7.20% |
| Mutual fund holders | 4.36% |
| Individual stakeholders | 12.06% |
Top Executives
| Uday Vijaykumar Baldota | Chief Executive Officer & Director |
| William J. Coote | Chief Financial, VP & Accounting Officer |
| Hagai Reingold | Vice President & Head-Operations |
| Itamar Karsenti | Vice President & Head-Operations |
| Avi Avramoff | Vice President & Head-Research & Development |
